[
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=cfb98e89bfb6cc4bf8693527cefe987a6baf1944d47c32d7bcf8af5a0451ba5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756848332,
      "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 136613195,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=cfb98e89bfb6cc4bf8693527cefe987a6baf1944d47c32d7bcf8af5a0451ba5a"
    }
  },
  {
    "ts": null,
    "headline": "Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?",
    "summary": "CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.",
    "url": "https://finnhub.io/api/news?id=65b2a75f8fb7f17a80f259ca29a6ceed99019487a93def96b25284b726a99e10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756826280,
      "headline": "Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?",
      "id": 136613196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.",
      "url": "https://finnhub.io/api/news?id=65b2a75f8fb7f17a80f259ca29a6ceed99019487a93def96b25284b726a99e10"
    }
  },
  {
    "ts": null,
    "headline": "Nicotine Gum Market Report 2025-2033 | Competitive Analysis of British American Tobacco, Cambrex, GlaxoSmithKline, ITC, Johnson & Johnson, Novartis, Perrigo, Pfizer, and Takeda",
    "summary": "The nicotine gum market is driven by smoking cessation initiatives and rising health awareness, leading to increased demand for OTC nicotine therapies. Technological advancements enhance product efficacy, and North America leads the market due to health-conscious consumers. Challenges include overcoming social stigmas. Nicotine Gum Market Nicotine Gum Market Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The \"Nicotine Gum Market Report by Type, and Region 2025-2033\" has been added to ResearchAndMark",
    "url": "https://finnhub.io/api/news?id=33c9ebbab7aeb6d59e547832b4b661f2535bd8fb6e6c7545c0a056616208f8ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756824300,
      "headline": "Nicotine Gum Market Report 2025-2033 | Competitive Analysis of British American Tobacco, Cambrex, GlaxoSmithKline, ITC, Johnson & Johnson, Novartis, Perrigo, Pfizer, and Takeda",
      "id": 136612897,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The nicotine gum market is driven by smoking cessation initiatives and rising health awareness, leading to increased demand for OTC nicotine therapies. Technological advancements enhance product efficacy, and North America leads the market due to health-conscious consumers. Challenges include overcoming social stigmas. Nicotine Gum Market Nicotine Gum Market Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The \"Nicotine Gum Market Report by Type, and Region 2025-2033\" has been added to ResearchAndMark",
      "url": "https://finnhub.io/api/news?id=33c9ebbab7aeb6d59e547832b4b661f2535bd8fb6e6c7545c0a056616208f8ff"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Stock Underperforming the Nasdaq?",
    "summary": "Although Pfizer has underperformed the Nasdaq recently, analysts remain moderately optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=9862a39812bb2317d14fde86a66fa02a1b951c7c0ece925d708b2783254e38f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756822056,
      "headline": "Is Pfizer Stock Underperforming the Nasdaq?",
      "id": 136613059,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Although Pfizer has underperformed the Nasdaq recently, analysts remain moderately optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=9862a39812bb2317d14fde86a66fa02a1b951c7c0ece925d708b2783254e38f1"
    }
  },
  {
    "ts": null,
    "headline": "Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer",
    "summary": "Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic breast cancer setting SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for bre",
    "url": "https://finnhub.io/api/news?id=445725da87260704fd9258124660145bc7b28c276175d7269d912c76b492a78a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756814400,
      "headline": "Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer",
      "id": 136604292,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic breast cancer setting SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for bre",
      "url": "https://finnhub.io/api/news?id=445725da87260704fd9258124660145bc7b28c276175d7269d912c76b492a78a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Pipeline Monetization Shows Great Promise - Rich Yields Pending Re-Rating",
    "summary": "PFE has shown great efforts in operational efficiencies, as observed in the richer profit margins, the expanding cash flows, and the healthier balance sheet.",
    "url": "https://finnhub.io/api/news?id=450fb25356e330dc70b0e0eb95072a60c5647529f95f0b1b8ede3222e24f9930",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756807800,
      "headline": "Pfizer: Pipeline Monetization Shows Great Promise - Rich Yields Pending Re-Rating",
      "id": 136606173,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132050/image_1359132050.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "PFE has shown great efforts in operational efficiencies, as observed in the richer profit margins, the expanding cash flows, and the healthier balance sheet.",
      "url": "https://finnhub.io/api/news?id=450fb25356e330dc70b0e0eb95072a60c5647529f95f0b1b8ede3222e24f9930"
    }
  },
  {
    "ts": null,
    "headline": "How AI advances will shape the drugmaker of the future",
    "summary": "An AI revolution is taking place, and leaders from tech to Big Pharma are forecasting what drugmakers of the future will look like.",
    "url": "https://finnhub.io/api/news?id=0688f0c47b84d362d6cacdaf440b978f2dde0a7d027a9c8029e214e7c1d85e9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756803600,
      "headline": "How AI advances will shape the drugmaker of the future",
      "id": 136613199,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "An AI revolution is taking place, and leaders from tech to Big Pharma are forecasting what drugmakers of the future will look like.",
      "url": "https://finnhub.io/api/news?id=0688f0c47b84d362d6cacdaf440b978f2dde0a7d027a9c8029e214e7c1d85e9a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE)’s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide",
    "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Pfizer Inc. stands fifth among them. Pfizer Inc. (NYSE:PFE), a global pharmaceutical leader, continues to drive growth through innovation, commercial execution, and operational efficiency. The company’s portfolio spans vaccines and treatments for a range of diseases, including its […]",
    "url": "https://finnhub.io/api/news?id=e99ce542b38dba73dd8eadd945eb35d6e2c62261fae0c8ba82c6a39deb5c7f7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756801689,
      "headline": "Pfizer Inc. (PFE)’s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide",
      "id": 136604293,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Pfizer Inc. stands fifth among them. Pfizer Inc. (NYSE:PFE), a global pharmaceutical leader, continues to drive growth through innovation, commercial execution, and operational efficiency. The company’s portfolio spans vaccines and treatments for a range of diseases, including its […]",
      "url": "https://finnhub.io/api/news?id=e99ce542b38dba73dd8eadd945eb35d6e2c62261fae0c8ba82c6a39deb5c7f7d"
    }
  },
  {
    "ts": null,
    "headline": "3 High-Yield Dividend Stocks You Can Buy in September and Hold Forever",
    "summary": "With an average yield above 6%, these stocks could do a lot to raise your passive income stream.",
    "url": "https://finnhub.io/api/news?id=877a9539bc34b94adc35f6d25b682ee0bebbe1a979608a7d4701c10086151dfb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756801260,
      "headline": "3 High-Yield Dividend Stocks You Can Buy in September and Hold Forever",
      "id": 136604294,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "With an average yield above 6%, these stocks could do a lot to raise your passive income stream.",
      "url": "https://finnhub.io/api/news?id=877a9539bc34b94adc35f6d25b682ee0bebbe1a979608a7d4701c10086151dfb"
    }
  }
]